Monte Rosa Therapeutics | 4:持股變動聲明-董事 Hughes Eric A
Monte Rosa Therapeutics | 3:首次持股聲明-董事 Hughes Eric A
Monte Rosa Therapeutics | 8-K:重大事件
Monte Rosa Therapeutics | 8-K:重大事件
Monte Rosa Therapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-T. ROWE PRICE ASSOCIATES, INC.(10.8%)
Monte Rosa Therapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-FMR LLC(8.312%),Abigail P. Johnson(8.312%)
Monte Rosa Therapeutics | 10-Q:2024財年三季報
Monte Rosa Therapeutics | 8-K:Monte Rosa Therapeutics公佈2024年第三季度財務業績並提供公司最新情況
Monte Rosa Therapeutics | SC 13D/A:超過5%持股股東披露文件(修正)-Versant Venture Capital VI, L.P.(6.6%),Versant Ventures VI GP, L.P.(6.6%)等
Monte Rosa Therapeutics | 4:持股變動聲明-股東 Versant Venture Capital VI, L.P.
Monte Rosa Therapeutics | 144:擬議出售證券
Monte Rosa Therapeutics | 8-K:重大事件
Monte Rosa Therapeutics | SC 13D/A:超過5%持股股東披露文件(修正)-Versant Venture Capital VI, L.P.(8.3%),Versant Ventures VI GP, L.P.(8.3%)等
Monte Rosa Therapeutics | 4:持股變動聲明-股東 Versant Venture Capital VI, L.P.
Monte Rosa Therapeutics | 4:持股變動聲明-股東 Versant Venture Capital VI, L.P.
Monte Rosa Therapeutics | 4:持股變動聲明-高管 Janku Filip
Monte Rosa Therapeutics | SC 13D/A:超過5%持股股東披露文件(修正)-Ali Behbahani(12.7%),New Enterprise Associates 17, L.P.(12.5%)等
Monte Rosa Therapeutics | SC 13D/A:超過5%持股股東披露文件(修正)-Versant Venture Capital VI, L.P.(11.1%),Versant Ventures VI GP, L.P.(11.1%)等
Monte Rosa Therapeutics | 10-Q:2024財年二季報
Monte Rosa Therapeutics | 8-K:Monte Rosa Therapeutics公佈2024年第二季度財務業績並提供公司最新情況
暫無數據